INTRODUCTION
Interleukin-10 (IL-10) is a pleiotropic cytokine that regulates the immune response by suppressing the production of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α. 1 For characterization of an inhibitory action of IL-10 on pro-inflammatory cytokine production, lipopolysaccharide (LPS), the outer membrane component of Gram-negative bacteria, has been utilized as an inducer of pro-inflammatory cytokine and chemokine release in macrophages. 1, 2 LPS activates macrophages via Toll-like receptor 4 (TLR4) and LPSinduced TLR4 stimulation results in the recruitment of MyD88 and TRIF (TIR-containing adaptor-inducing interferons) to the cytoplasmic domain of TLR4. MyD88 triggers activation of nuclear factor (NF)-κB and mitogen-activated protein kinases (MAPKs) in a MyD88-dependent signal pathway. On the other hand, TRIF triggers MyD88-independent signal pathway via interferon regulatory factor (IRF)-3. Those signal pathways are involved in the production of pro-inflammatory cytokines and mediators in macrophages. [3] [4] [5] Many attempts have been made to elucidate the molecular mechanism by which IL-10 inhibits the production of pro-inflammatory cytokines in LPS-stimulated macrophages. In fact, IL-10 is known to inhibit LPSinduced TNF-α production by inhibiting activation of NF-κB 6, 7 or p38 MAPK, 8 and by inducing suppressor of cytokine signaling (SOCS)-3. 9 However, the precise mechanism by which IL-10 suppresses LPS-induced TNF-α production remains controversial. In the present study, we studied an inhibitory action of IL-10 on TNF-α production in LPS-stimulated RAW 264.7 macrophage cells. Here, we demonstrate that IL-10 may inhibit LPS-induced TNF-α production via reduced MyD88 expression and subsequent impaired activation of NF-κB, p38 and stress-activated protein kinase (SAPK/JNK).
MATERIALS AND METHODS

Reagents
LPS from Escherichia coli serotype O55 was obtained from Sigma-Aldrich (St Louis, MO, USA). Recombinant murine IL-10 was purchased from Peprotech (London, UK). Poly I:C was obtained from InvivoGen (San Diego, CA, USA). Antibodies to MyD88 and TRIF/TICAM were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and Imgenex (San Diego, CA, USA), respectively.
Cell culture
The murine macrophage cell line RAW 264.7 was obtained from the Health Science Resource Bank (Tokyo, Japan), and maintained in DMEM medium (Sigma) containing 10% heat-inactivated fetal calf serum (Life Technologies; Grand Island, NY, USA) supplemented with 2 mM L-glutamine, 200 U/ml penicillin, 100 µg/ml streptomycin at 37°C with 5% CO 2 . The cells were washed gently with saline, removed from the flasks and used for experiments.
Reverse transcription-polymerase chain reaction (RT-PCR) and real time PCR
RAW 264.7 cells (3 x 10 6 /ml) were pretreated with IL-10 at 15 ng/ml for 1 h and stimulated with LPS at 50 ng/ml for various periods (hours), unless otherwise stated. Total RNA was isolated from cells using TRIzol reagent (Invitrogen; Grand Island, NY, USA) in accordance with the manufacturer's protocols. Total RNA was reversetranscribed to cDNA using a RT system with random hexamers (Toyobo; Tokyo, Japan). Expression of mRNA was analyzed by using ABI prism 7700, according to the manufacturer's instructions (Applied Biosystems; Foster City, CA, USA). The reaction mixture consists of SYBR green PCR master mix (Toyobo) and following sequence-specific primers: β-actin sense (ATGACCCA-GATC ATGTTTGA), β-actin antisense (TACGACCA-GAGG CATACAG); MyD88 sense (GGAGCCAGATTCTC TGATGC), MyD88 antisense (CCTA GTTGCTCAGGCCAGTC); TRIF sense (CCAGCCA CCTAGAGATCAGC), TRIF antisense (TGTCCAGCGGTGTGTTACAT).
Determination of TNF-α
RAW 264.7 cells (5 x 10 4 /well in a 96-well microplate) were pretreated with IL-10 at 15 ng/ml for 1 h and stim-ulated with LPS at 50 ng/ml for various hours. The concentration of TNF-α in the culture supernatant was determined with an enzyme-linked immunosorbent assay (ELISA) kit from Biosource (Camarillo, CA, USA). For each group, the mean of three wells with SD is expressed.
Transient transfection
RAW 264.7 cells were plated at 1 x 10 5 cells per well in a 48-well plate 24 h before the study. The cells were transiently transfected with the luciferase reporter gene construct the pNF-κB-TA (BD Biosciences Clontech; Palo Alto, CA, USA) using lipofectamine 2000 (Gibco-BRL; Gaithersburg, MD, USA). The cells were pretreated with IL-10 (15 ng/ml) for 1 h and then stimulated with LPS (50 ng/ml) for various hours. The cells were lysed and the luciferase activity was determined with a luminometer. The relative luciferase activity was calculated by the β-galactosidase activity as a normalizing factor.
Immunoblotting and immunoprecipitation
RAW 264.7 cells were treated with IL-10 (15 ng/ml) for 1 h and stimulated with LPS (50 ng/ml) for 2 h. Stimulated cells (5 x 10 6 ) were lysed in lysis buffer containing 50 mM HEPES (pH 7.9), 1% Nonidet P-40, 1 mM EDTA, 250 mM NaCl, 20 mM β-glycerophosphate, 1 mM orthovanadate, and protease inhibitors. The protein concentration of the samples was determined by the BCA protein assay reagent (Pierce; Rockford, IL, USA). Each cell lysate containing 60 µg of protein was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis with 10% gel under reducing conditions and transferred to the membranes. The membranes were blocked with 5% skimmed milk and treated with appropriately diluted antibodies to various signal molecules overnight. The immune complexes were detected with a 1:1000 dilution of horseradish peroxidase-conjugated anti-rabbit IgG antibody and the bands were visualized with a chemiluminescent reagent (Pierce). The chemiluminescence was analyzed by a light capture system (AE6955: Atto Corp.; Tokyo, Japan) with a CS analyzer. For characterization of MyD88 expression, the cell lysates were incubated with anti-MyD88 antibody (1:100) and immunoprecipitated by anti-rabbit Ig IP beads (eBioscience; San Diego, CA, USA) according to the manufacturer's instruction. The immunoprecipitated samples were further analyzed by gel electrophoresis and immunoblotting with anti-MyD88 antibody (1:200).
Laser flow cytometric analysis
RAW 264.7 cells (5 x 10 6 ) were permeabilized by a permeabilization buffer (eBioscience) according to the procedure of the manufacturer. The cells were stained with a 1:100 dilution of antibody to TICAM/TRIF for 40 min on ice and further with fluorescein-conjugated secondary antibody (Cappel; West Chester, PA, USA) for 20 min. The expression of TRIF on RAW 264.7 cells was analyzed by a laser flow cytometer (FACS Calibur: Becton Dickinson; Palo Alto, CA, USA). Approximately 10,000 cells were measured and the fluorescence intensity is expressed on a log scale from 1 to 10 3 .
Statistical analysis
Statistical analysis was performed using Student's t-test, with P < 0.0 1 considered to indicate a significant differ-ence. Experimental results are expressed as the mean value of triplicates with SD in at least three independent experiments.
RESULTS
IL-10 inhibits TNF-α production in LPS-stimulated RAW 264.7 cells
The effect of IL-10 on LPS-induced TNF-α production was examined by using RAW 264.7 murine macrophage cells. RAW 264.7 cells were treated with 5-50 ng/ml of IL-10 for 1 h and then stimulated with LPS at 50 ng/ml for 2 h. The level of TNF-α in the culture supernatant was determined with ELISA. As shown in Figure 1A , IL-10 at 15 ng/ml and higher significantly inhibited TNF-α production in LPS-stimulated RAW 264.7 cells. There was no significant difference in the inhibitory action among the concentrations of IL-10 at 15, 30 and 50 ng/ml.
The time course of LPS-induced TNF-α production in IL-10-pretreated RAW 264.7 cells was followed ( Fig.  1B) . IL-10 inhibited LPS-induced TNF-α production 1 h and 2 h after LPS treatment. On the other hand, there was no significant difference in TNF-α production 0.5 h and 4 h after LPS treatment between cells pretreated with or without IL-10, suggesting a transient inhibition of LPS-induced TNF-α production by IL-10. The experimental result was consistent with the previous report that IL-10 exclusively inhibits an early stage of LPSinduced TNF-α production. 9
IL-10 inhibits activation of NF-κB, p38 and SAPK/JNK in LPS-stimulated RAW 264.7 cells
LPS-induced TNF-α production is mainly dependent on MyD88-dependent NF-κB activation. 10, 11 The effect of IL-10 on NF-κB activation in LPS-stimulated RAW 264.7 cells was examined by a luciferase reporter gene assay ( Fig. 2A) . Transiently transfected RAW 264.7 cells were pretreated with IL-10 (15 ng/ml) for 1 h and then stimulated with LPS (50 ng/ml) for 15-240 min. LPS caused a marked increase in the luciferase activity in RAW 264.7 cells. On the other hand, IL-10 significantly prevented the LPS-induced NF-κB activation at 1 h and 2 h , but not 4 h, after LPS administration.
MAPKs, such as p38 and SAPK/JNK, have been previously demonstrated to modulate TNF-α biosynthesis. 8 Therefore, we examined the effect of IL-10 on activation of p38 and SAPK/JNK in LPS-stimulated RAW 264.7 cells with immunoblotting using antibodies to native and phosphorylated forms (Fig. 2B ). IL-10 inhibited LPSinduced phosphorylation of p38 and SAPK/JNK 15 min Interleukin-10 inhibits TNF-α production in LPS-stimulated RAW 264.7 cells 111 Fig. 1 . IL-10 inhibits TNF-α production in LPS-stimulated RAW 264.7 cells. (A) RAW 264.7 cells were pretreated with various concentrations of IL-10 for 1 h and stimulated with LPS (50 ng/ml) for 2 h. The concentration of TNF-α in the supernatant was determined with ELISA and the mean of triplicates ± SD is expressed. One of three independent experiments is shown. *P < 0.01 versus LPS alone. (B) RAW 264.7 cells were pretreated with IL-10 (15 ng/ml) for 1 h and stimulated with LPS (50 ng/ml) for the indicated time. The fold increase of TNF-α level was calculated based on the value at 0 h and is expressed as the mean of triplicates in two independent experiments. *P < 0.01 versus LPS alone.
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and 30 min after LPS treatment and the level of their native forms remained unchanged. This result suggested that IL-10 impaired the upstream molecules regulating activation of NF-κB, p38 and SAPK/JNK.
IL-10 prevents LPS-induced augmentation of MyD88 protein, but not MyD88 mRNA
LPS triggers TLR4-mediated signal transduction consisting of MyD88-dependent and MyD88-independent pathways. The MyD88-dependent pathway regulates activation of NF-κB, p38 and SAPK/JNK for TNF-α production. [12] [13] [14] Therefore, the effect of IL-10 on the expression of MyD88 protein and mRNA was examined in LPS-stimulated RAW 264.7 cells (Fig. 3) . First, RAW 264.7 cells were treated with IL-10 at 1 ng/ml or 15 ng/ml for 1 h and stimulated with LPS (50 ng/ml) for 2 h. Cellular lysates were immunoprecipitated and then analyzed by immunoblotting using an anti-MyD88 antibody. As shown in Figure 3A , the cells pretreated with 15 ng of IL-10 expressed a lower level of MyD88 2 h after LPS treatment than cells pretreated with no or 1 ng of IL-10. However, there was no significant difference in MyD88 expression between them 4 h after LPS treatment (data not shown). Subsequently, we examined LPSinduced MyD88 expression in the cells pretreated with IL-10 (15 ng/ml) for 0, 30 or 60 min. The cells pretreated with IL-10 for 30 min or 60 min expressed a lower level of MyD88 (Fig. 3B) .
Further, the expression of MyD88 mRNA was determined by real-time PCR. RAW 264.7 cells were treated with IL-10 (15 ng/ml) for 1 h and stimulated with LPS for various times. As shown in Figure 3C , there was no significant difference in the level of MyD88 mRNA expression after LPS stimulation between the cells pretreated with or 112 Dagvadorj, Naiki, Tumurkhuu et al. 
IL-10 does not affect the level of TRIF expression in MyD88-independent pathway in LPS-stimulated RAW 264.7 cells
In the preceding section, IL-10 was shown to prevent LPS-induced augmentation of MyD88 expression in the MyD88-dependent pathway. In order to verify the action of IL-10 on the MyD88-independent pathway, the effect of IL-10 on the expression of TRIF mRNA and protein was examined by real-time PCR and FACS analysis. RAW 264.7 cells were pretreated with IL-10 (15 ng/ml) and stimulated with LPS (50 ng/ml) for various times. As shown in Figure 4A , there was no significant difference in the TRIF mRNA expression level between the cells pretreated with or without IL-10 in response to LPS. Next, RAW 264.7 cells were pretreated with IL-10 and stimulated with LPS. The cells were permeabilized for detection of intracellular TRIF expression. FACS analysis demonstrated that there was no significant difference in intracellular TRIF expression between cells Interleukin-10 inhibits TNF-α production in LPS-stimulated RAW 264.7 cells 113 B A C Fig. 3 . IL-10 reduces the expression of MyD88 protein, but not MyD88 mRNA, in LPS-stimulated RAW 264.7 cells. (A) RAW 264.7 cells were pretreated with IL-10 (1 or 15 ng/ml) for 1 h and stimulated with LPS (50 ng/ml) for 2 h. (B) RAW 264.7 cells were pretreated with IL-10 (15 ng/ml) for 0, 30 or 60 min and stimulated with LPS (50 ng/ml) for 2 h. MyD88 protein expression was analyzed by immunoprecipitation and immunoblotting with anti-MyD88 antibody. One of three independent experiments is shown. (C) RAW 264.7 cells were pretreated with IL-10 (15 ng/ml) for 1 h and stimulated with LPS (50 ng/ml) for the indicated time. MyD88 mRNA expression was analyzed by real-time PCR. One of three independent experiments is shown. Fig. 4 . IL-10 does not inhibit the expression of TRIF in LPS-stimulated RAW 264.7 cells. RAW 264.7 cells were pretreated with IL-10 (15 ng/ml) for 1 h and stimulated with LPS (50 ng/ml) for the indicated time. (A) TRIF mRNA expression was analyzed by real-time PCR. One of two experiments is shown. (B) RAW 264.7 cells were pretreated with IL-10 (15 ng/ml) for 1 h and stimulated with LPS (50 ng/ml) for 2 h. The intracellular expression of TRIF protein was determined by FACS analysis using permeabilized cells and anti-TRIF antibody. One of three independent experiments is shown. pretreated with or without IL-10 in response to LPS (Fig.  4B ), suggesting no alteration in TRIF expression of the cells pretreated with IL-10. This result suggested that IL-10 inhibited the TLR4-mediated MyD88-dependent signal pathway, but not the MyD88-independent pathway.
A B
DISCUSSION
In the present study, we demonstrate that IL-10 may inhibit TNF-α production in LPS-stimulated RAW 264.7 cells via reduced MyD88 expression. LPS augments the expression of MyD88 in untreated cells, but not in IL-10-pretreated cells. The inhibitory action of IL-10 on LPS-induced MyD88 augmentation may cause an impaired activation of NF-κB, p38 and SAPK/JNK because they are the downstream molecules of MyD88 in the LPS signal pathway. The impaired activation of NF-κB, p38 and SAPK/JNK probably prevents LPSinduced TNF-α production in IL-10-pretreated RAW 264.7 cells. IL-10 is known to exhibit anti-inflammatory action by inhibiting the transcription factor, such as NF-κB. 15, 16 On the other hand, IL-10-mediated suppression of TNF-α production is reported to be independent of its ability to inhibit NF-κB activity. 17, 18 Moreover, the dominant mediators of the majority of IL-10 functions have been reported to be the induction of suppressor of cytokine signaling (SOCS)-3 probably via a STAT3-dependent pathway and bcl-3 in its anti-inflammatory activity. SOCS3 seems to attenuate pro-inflammatory aspects of TLR signaling directly. [19] [20] [21] [22] However, the present study suggests that IL-10 may exhibit the anti-inflammatory action via reduced MyD88 expression. In fact, MyD88 deficiency is known to lead to diminished inflammatory cytokine production. 23, 24 This is the first report on the crosstalk between IL-10 and MyD88 in TLR-mediated signaling, as far as is known. IL-10 prevents LPS-induced augmentation of MyD88 protein without altering the mRNA level. The IL-10mediated reduction of MyD88 protein might be dependent on degradation. Recently, TGF-β1 has been reported to block the NF-κB activation and cytokine release that is stimulated by ligands for TLR2, TLR4, and TLR5 and that TGF-β1 specifically interferes with MyD88-dependent signaling by decreasing MyD88 protein levels without altering its mRNA expression. 25 Therefore, IL-10 and TGF-β1 may utilize a common mechanism for expression of their function. The idea is consistent with the recent review stating that antiinflammatory cytokines might regulate pro-inflammatory cytokine production by degradation of MyD88 protein. 26 IL-10 did not affect the expression of TRIF that triggers the MyD88-independent pathway of LPS signaling.
TRIF is also a key molecule in TLR3-mediated signaling, which activates NF-κB with no involvement of MyD88. 27 In fact, we found that IL-10 did not inhibit the TLR3-dependent production of nitric oxide (NO) in poly I:C-stimulated RAW 264.7 cells (data not shown), suggesting that IL-10 may exclusively interfere with the function of MyD88. On the other hand, IL-10 inhibited CpG DNA-induced NO production. This would be reasonable because CpG DNA stimulates TLR9-mediated signaling which involves MyD88 molecule.
The inhibitory action of IL-10 is restricted to an early stage (1-2 h) of LPS-induced TNF-α production. The early inhibition by IL-10 of LPS-induced TNF-α production is consistent with the previous report by Qasimi et al. 9 There was no difference in the TNF-α production at a late stage between cells pretreated with or without IL-10. Lack of inhibition of the TNF-α production at a late stage after LPS stimulation could be explained by recovery of MyD88 expression. The reduction of MyD88 in IL-10-pretreated cells would be closely related to the transient inhibition of LPS-induced TNF-α production at an early stage.
